StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) company profile

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

About Zevra Therapeutics

Pharmaceutical Preparations, SIC 2834

Zevra Therapeutics, Inc. is a pharmaceutical company that develops and commercializes therapies for rare diseases. Its commercial products include MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for attention deficit hyperactivity disorder, marketed through partners. The company also advances clinical candidates such as celiprolol for vascular Ehlers-Danlos syndrome and KP1077 for sleep disorders. Its products serve adult and pediatric patients with rare neurodegenerative, metabolic, and genetic conditions.

The company distributes products in the United States and provides MIPLYFFA in France, Germany, other European Union nations, and select global markets via an expanded access program. It is also seeking regulatory approval across the European Union. Partner agreements grant commercialization rights in European countries and Greater China. Furthermore, the company holds active patents across North America, Europe, Asia, and other territories. The excerpt does not mention the company's headquarters location.

Summary of the business section of Zevra Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Zevra Therapeutics, Inc.
Headquarters
Boston, MA
Address
101 Federal Street 02110
Phone
(888) 958-1253
Website
zevra.com
Employees
61, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Orlando, Florida

Stock & identifiers

Ticker
ZVRA
Former tickers
KMPH until Mar 7, 2023
Exchange
Nasdaq
IPO date
Apr 16, 2015
Shares outstanding
59M, Jul 31, 2026
Public float
$454.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-16 reverse, Dec 28, 2020
SEC CIK
1434647
CUSIP
488445206
ISIN
US4884452065
FIGI
BBG0026ZG1F5
Share class FIGI
BBG0026ZG1G4
LEI
254900CU6T74V18Y1W18
EIN
20-5894398

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Neil F. McFarlanePresident and CEO, Director417,225
Rahsaan ThompsonChief Legal & Compliance37,569
Timothy J. SangiovanniSVP, Finance & Corp Controller29,590
Justin A. RenzCFO–
Joshua SchaferCCO62,278
Adrian W. QuartelChief Medical Officer14,256
Corey Michael WattonDirector1,800
Thomas AndersonDirector20,000
Tamara A. FavoritoDirector3,894
Alicia SecorDirector–
Alvin ShihDirector20,000
Douglas W. CalderDirector–
John B. BodeDirector123,400
Wendy L. DixonDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.78M$4.00M$2.70M–$195
FY2024$5.36M$7.32M$1.98M–$182
FY2023
Christal M.Mickle
$1.67M$2.21M$2.04M–$143
FY2023
Current CEO
$3.45M$4.98M$2.04M–$143
FY2023
Former CEO1
$3.59M$4.39M$2.04M–$143
FY2023
Former CEO2
$4.12M$3.31M$2.04M–$143

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Neil F. McFarlane
President, Chief Executive Officer and Director
$729.17K–$874.13K$1.75M$418.95K$11.55K$3.78M-29%
Rahsaan W. Thompson
Chief Legal Officer, Secretary and Compliance Officer
$466.67K$50.00K$272.68K$545.36K$178.60K$58.07K$1.57M–
R. LaDuane Clifton
Former Chief Financial Officer and Treasurer
$477.31K–$1.26M$1.12M–$966.97K$3.82M+164%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 16, 2015
Offer price
$11.00
Securities offered
5,090,909
Gross proceeds
$56.00M
Exchange
Nasdaq
First trading day
Apr 16, 2015
First-day close
$11.20+1.8%
Lock-up ends (est.)
Oct 13, 2015

“Our common stock has been approved for listing on The NASDAQ Global Market under the symbol “KMPH.” The initial public offering price is $11.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 61 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 7, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 20, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 29, 2023MergerRegistration of securities for a merger or exchange offer (S-4)
Feb 24, 2023Name changeName changed from KEMPHARM, INC to Zevra Therapeutics, Inc.
Jun 17, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 1, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 5, 2021ListingRegistration of securities on an exchange (Form 8-A)
Oct 29, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 11, 2020DelistingNotice of delisting from exchange (Form 25)
May 20, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 2, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 16, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 23, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 21, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 3, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 23, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 19, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2017Late filingNotification of late filing
Mar 28, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 16, 2015IPOInitial public offering priced (424B4 prospectus)
Apr 10, 2015ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?